Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Purchases 9,004 Shares of Company Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 9,004 shares of the stock in a transaction on Friday, October 30th. The shares were purchased at an average price of $26.28 per share, with a total value of $236,625.12. Following the acquisition, the insider directly owned 6,850,237 shares in the company, valued at $180,024,228.36. This represents a 0.13% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, October 29th, Venrock Healthcare Capital Par acquired 1,000 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $26.33 per share, for a total transaction of $26,330.00.
• On Wednesday, October 28th, Venrock Healthcare Capital Par acquired 15,000 shares of Lycia Therapeutics stock. The shares were purchased at an average cost of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The shares were purchased at an average cost of $26.62 per share, with a total value of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Stock Performance

NASDAQ:LYCA opened at $26.40 on Friday. Lycia Therapeutics, Inc. has a 12 month low of $22.19 and a 12 month high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.